{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T20:49:58Z","timestamp":1773002998868,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s11894-008-0024-9","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T16:15:52Z","timestamp":1205770552000},"page":"74-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Chelation therapy for iron overload"],"prefix":"10.1007","volume":"9","author":[{"given":"James C.","family":"Barton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,18]]},"reference":[{"key":"24_CR1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7326\/0003-4819-129-11_Part_2-199812011-00003","volume":"129","author":"J.C. Barton","year":"1998","unstructured":"Barton JC, McDonnell SM, Adams PC, et al.: Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998, 129:932\u2013939.","journal-title":"Ann Intern Med"},{"key":"24_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","volume":"360","author":"L.J. Anderson","year":"2002","unstructured":"Anderson LJ, Wonke B, Prescott E, et al.: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002, 360:516\u2013520.","journal-title":"Lancet"},{"key":"24_CR3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/beha.2002.0209","volume":"15","author":"D.Y. Liu","year":"2002","unstructured":"Liu DY, Liu ZD, Hider RC: Oral iron chelators: development and application. Best Pract Res Clin Haematol 2002, 15:369\u2013384.","journal-title":"Best Pract Res Clin Haematol"},{"key":"24_CR4","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2002-01-0306","volume":"100","author":"I.R. Wanless","year":"2002","unstructured":"Wanless IR, Sweeney G, Dhillon AP, et al.: Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002, 100:1566\u20131569.","journal-title":"Blood"},{"key":"24_CR5","first-page":"327","volume":"6","author":"J.C. Barton","year":"2005","unstructured":"Barton JC: Deferasirox Novartis. Curr Opin Investig Drugs 2005, 6:327\u2013335.","journal-title":"Curr Opin Investig Drugs"},{"key":"24_CR6","first-page":"5A","volume":"100","author":"A. Piga","year":"2002","unstructured":"Piga A, Galanello R, Cappelini MD, et al.: Phase II Study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood 2002, 100:5A.","journal-title":"Blood"},{"key":"24_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.beha.2004.09.002","volume":"18","author":"M.D. Cappellini","year":"2005","unstructured":"Cappellini MD: Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005, 18:289\u2013298.","journal-title":"Best Pract Res Clin Haematol"},{"key":"24_CR8","first-page":"809","volume":"91","author":"A. Kattamis","year":"2006","unstructured":"Kattamis A, Papassotiriou I, Palaiologou D, et al.: The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006, 91:809\u2013812.","journal-title":"Haematologica"},{"key":"24_CR9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","volume":"22","author":"L.J. Anderson","year":"2001","unstructured":"Anderson LJ, Holden S, Davis B, et al.: Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001, 22:2171\u20132179.","journal-title":"Eur Heart J"},{"key":"24_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000089475","volume":"115","author":"L.J. Anderson","year":"2006","unstructured":"Anderson LJ, Westwood MA, Prescott E, et al.: Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 2006, 115:106\u2013108.","journal-title":"Acta Haematol"},{"key":"24_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199409013310903","volume":"331","author":"N.F. Olivieri","year":"1994","unstructured":"Olivieri NF, Nathan DG, MacMillan JH, et al.: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994, 331:574\u2013578.","journal-title":"N Engl J Med"},{"key":"24_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000203853","volume":"95","author":"V. Gabutti","year":"1996","unstructured":"Gabutti V, Piga A: Results of long-term iron-chelating therapy. Acta Haematol 1996, 95:26\u201336.","journal-title":"Acta Haematol"},{"key":"24_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJM199409013310902","volume":"331","author":"G.M. Brittenham","year":"1994","unstructured":"Brittenham GM, Griffith PM, Nienhuis AW, et al.: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331:567\u2013573.","journal-title":"N Engl J Med"},{"key":"24_CR14","first-page":"489","volume":"88","author":"A. Piga","year":"2003","unstructured":"Piga A, Gaglioti C, Fogliacco E, Tricta F: Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003, 88:489\u2013496.","journal-title":"Haematologica"},{"key":"24_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","volume":"102","author":"A.V. Hoffbrand","year":"2003","unstructured":"Hoffbrand AV, Cohen A, Hershko C: Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003, 102:17\u201324.","journal-title":"Blood"},{"key":"24_CR16","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1046\/j.1365-2141.2003.04297.x","volume":"121","author":"R. Fischer","year":"2003","unstructured":"Fischer R, Longo F, Nielsen P, et al.: Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003, 121:938\u2013948.","journal-title":"Br J Haematol"},{"key":"24_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1046\/j.1365-2141.1998.01002.x","volume":"103","author":"B. Wonke","year":"1998","unstructured":"Wonke B, Wright C, Hoffbrand AV: Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998, 103:361\u2013364.","journal-title":"Br J Haematol"},{"key":"24_CR18","first-page":"1420","volume":"91","author":"A. Ceci","year":"2006","unstructured":"Ceci A, Baiardi P, Cataprano M, et al.: Risk factors for death in patients with beta-thalassemia major: results of a case-control study. Haematologica 2006, 91:1420\u20131421.","journal-title":"Haematologica"},{"key":"24_CR19","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"M.D. Cappellini","year":"2006","unstructured":"Cappellini MD, Cohen A, Piga A, et al.: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006, 107:3455\u20133462.","journal-title":"Blood"},{"key":"24_CR20","first-page":"ELT04","volume":"91","author":"G.J. Kontoghiorghes","year":"2006","unstructured":"Kontoghiorghes GJ, Kolnagou A: Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs. Haematologica 2006, 91:ELT04.","journal-title":"Haematologica"},{"key":"24_CR21","doi-asserted-by":"crossref","unstructured":"Darbari DS, Kple-Faget P, Kwagyan J, et al.: Circumstances of death in adult sickle cell disease patients. Am J Hematol August 21, 2006 [epub]; DOI 10.1002\/ajh.20685.","DOI":"10.1002\/ajh.20685"},{"key":"24_CR22","doi-asserted-by":"crossref","unstructured":"Kearney SL, Nemeth E, Neufeld EJ, et al.: Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer August 11, 2005 [epub]; DOI 10.1002\/pbc.20616.","DOI":"10.1002\/pbc.20616"},{"key":"24_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bcmd.2005.01.001","volume":"34","author":"J.C. Barton","year":"2005","unstructured":"Barton JC, Lee PL, Bertoli LF, Beutler E: Iron overload in an African American woman with SS hemoglobinopathy and a promoter mutation in the X-linked erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. Blood Cells Mol Dis 2005, 34:226\u2013228.","journal-title":"Blood Cells Mol Dis"},{"key":"24_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1182\/blood-2005-10-009506","volume":"108","author":"M.T. Lee","year":"2006","unstructured":"Lee MT, Piomelli S, Granger S, et al.: Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006, 108:847\u2013852.","journal-title":"Blood"},{"key":"24_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/pbc.20290","volume":"44","author":"M.J. Treadwell","year":"2005","unstructured":"Treadwell MJ, Law AW, Sung J, et al.: Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer 2005, 44:500\u2013507.","journal-title":"Pediatr Blood Cancer"},{"key":"24_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00277-005-1015-7","volume":"84","author":"E. Voskaridou","year":"2005","unstructured":"Voskaridou E, Douskou M, Terpos E, et al.: Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol 2005, 84:434\u2013440.","journal-title":"Ann Hematol"},{"key":"24_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1517\/13543784.15.8.833","volume":"15","author":"I. Okpala","year":"2006","unstructured":"Okpala I: Investigational agents for sickle cell disease. Expert Opin Investig Drugs 2006, 15:833\u2013842.","journal-title":"Expert Opin Investig Drugs"},{"key":"24_CR28","doi-asserted-by":"crossref","unstructured":"Beutler E, Hoffbrand AV, Cook JD: Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003, 40\u201361.","DOI":"10.1182\/asheducation-2003.1.40"},{"key":"24_CR29","doi-asserted-by":"crossref","unstructured":"Porter J, Vichinsky E, Rose C, et al.: A phase II study with ICL670 (Exjade), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload. Blood 2004, 104.","DOI":"10.1182\/blood.V104.11.3193.3193"},{"key":"24_CR30","unstructured":"Gattermann N: Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators. Hematol Oncol Clin 2006, 13\u201317."},{"key":"24_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1246-7820(01)00193-8","volume":"8","author":"C. Rose","year":"2001","unstructured":"Rose C, Cambier N, Mahieu M, et al.: [Iron overload and myelodysplastic syndromes]. Transfus Clin Biol 2001, 8:422\u2013432.","journal-title":"Transfus Clin Biol"},{"key":"24_CR32","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","volume":"23","author":"L. Malcovati","year":"2005","unstructured":"Malcovati L, Porta MG, Pascutto C, et al.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594\u20137603.","journal-title":"J Clin Oncol"},{"key":"24_CR33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.6004\/jnccn.2006.0010","volume":"4","author":"P.L. Greenberg","year":"2006","unstructured":"Greenberg PL, Baer MR, Bennett JM, et al.: Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4:58\u201377.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl1","key":"24_CR34","first-page":"S76","volume":"29","author":"N. Gattermann","year":"2005","unstructured":"Gattermann N, Cazzola M, Greenberg P, et al.: The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndromes (MDS) and iron overload. Leuk Res 2005, 29(Suppl 1):S76.","journal-title":"Leuk Res"},{"key":"24_CR35","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1053\/gast.2001.21913","volume":"120","author":"B.R. Bacon","year":"2001","unstructured":"Bacon BR: Hemochromatosis: diagnosis and management. Gastroenterology 2001, 120:718\u2013725.","journal-title":"Gastroenterology"},{"key":"24_CR36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.21260","volume":"44","author":"L. Falize","year":"2006","unstructured":"Falize L, Guillygomarc\u2019h A, Perrin M, et al.: Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006, 44:472\u2013477.","journal-title":"Hepatology"},{"key":"24_CR37","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1111\/j.1572-0241.2003.07292.x","volume":"98","author":"B.L. Hicken","year":"2003","unstructured":"Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003, 98:2072\u20132077.","journal-title":"Am J Gastroenterol"},{"key":"24_CR38","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1046\/j.1365-2141.2003.04708.x","volume":"123","author":"P. Nielsen","year":"2003","unstructured":"Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 2003, 123:952\u2013953.","journal-title":"Br J Haematol"},{"key":"24_CR39","first-page":"308","volume":"41","author":"J. Barr","year":"1999","unstructured":"Barr J, Berkovitch M, Tavori I, et al.: Acute iron intoxication: the efficacy of deferiprone and sodium biocarbonate in the prevention of iron absorption from the digestive tract. Vet Hum Toxicol 1999, 41:308\u2013311.","journal-title":"Vet Hum Toxicol"},{"key":"24_CR40","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0016-5085(94)90235-6","volume":"107","author":"B.R. Bacon","year":"1994","unstructured":"Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103\u20131109.","journal-title":"Gastroenterology"},{"key":"24_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000081277","volume":"112","author":"J.C. Barton","year":"2004","unstructured":"Barton JC, Felitti VJ, Lee P, Beutler E: Characteristics of HFE C282Y homozygotes younger than age 30 years. Acta Haematol 2004, 112:219\u2013221.","journal-title":"Acta Haematol"},{"key":"24_CR42","first-page":"16","volume":"14","author":"P.C. Adams","year":"1991","unstructured":"Adams PC, Bradley C, Frei JV: Hepatic zinc in hemochromatosis. Clin Invest Med 1991, 14:16\u201320.","journal-title":"Clin Invest Med"},{"key":"24_CR43","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1046\/j.1537-2995.2001.41060819.x","volume":"41","author":"C.D. Bolan","year":"2001","unstructured":"Bolan CD, Conry-Cantilena C, Mason G, et al.: MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001, 41:819\u2013827.","journal-title":"Transfusion"},{"key":"24_CR44","doi-asserted-by":"crossref","unstructured":"Fabio G, Minonzio F, Delbini P, et al.: Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by severe type of juvenile hemochromatosis (JH). Blood September 7, 2006 [epub]; DOI 10.1182\/blood-2006-04-016949.","DOI":"10.1182\/blood-2006-04-016949"},{"key":"24_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJM199201093260204","volume":"326","author":"V. Gordeuk","year":"1992","unstructured":"Gordeuk V, Mukiibi J, Hasstedt SJ, et al.: Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992, 326:95\u2013100.","journal-title":"N Engl J Med"},{"key":"24_CR46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1079-9796(03)00166-9","volume":"31","author":"J.C. Barton","year":"2003","unstructured":"Barton JC, Acton RT, Rivers CA, et al.: Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis 2003, 31:310\u2013319.","journal-title":"Blood Cells Mol Dis"},{"key":"24_CR47","first-page":"895","volume":"51","author":"A.N. Speight","year":"1974","unstructured":"Speight AN, Cliff J: Iron storage disease of the liver in Dar es Salaam: a preliminary report on venesection therapy. East Afr Med J 1974, 51:895\u2013902.","journal-title":"East Afr Med J"},{"key":"24_CR48","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ajh.20714","volume":"81","author":"J.C. Barton","year":"2006","unstructured":"Barton JC, Lee PL, West C, Bottomley SS: Iron overload and prolonged ingestion of iron supplements: Clinical features and mutation analysis of hemochromatosis-associated genes in four cases. Am J Hematol 2006, 81:760\u2013767.","journal-title":"Am J Hematol"},{"key":"24_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/03630260500455615","volume":"30","author":"A. Meo","year":"2006","unstructured":"Meo A, Ruggeri A, La Rosa MA, et al.: Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. Hemoglobin 2006, 30:131\u2013137.","journal-title":"Hemoglobin"},{"key":"24_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00000441-200002000-00001","volume":"319","author":"J.C. Barton","year":"2000","unstructured":"Barton JC, Bertoli LF: Transfusion iron overload in adults with acute leukemia: manifestations and therapy. Am J Med Sci 2000, 319:73\u201378.","journal-title":"Am J Med Sci"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-008-0024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-008-0024-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-008-0024-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-008-0024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T21:14:26Z","timestamp":1708722866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-008-0024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s11894-008-0024-9","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"18 March 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}